Q4 & FY22 Highlights slide image

Q4 & FY22 Highlights

Dr. Lal PathLabs - At a Glance India's Leading & Trusted Diagnostics Company 70+ years of experience in the field of diagnostics 100 Mn patients serviced in last 5 years 31 NABL accredited Labs; National Reference Lab accredited by CAP Largest* diagnostics chain in the country with PAN India presence and consistent track record of quality and growth 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 344 crore (Net) Cash & Investments as on 4,731 Patient Service Centres (PSC's) 31st Mar, 22 5,113 Pathology & Radiology tests; Comprehensive Test menu As on March 31, 2022 *Largest on the basis of revenue and presence Note: Figures includes Suburban Diagnostics w.e.f. 12th November 2021 5 Dr Lal PathLabs
View entire presentation